Logo

Cynvenio ClearID Breast Cancer Test

Jan 09, 2017

Cynvenio Biosystems released its updated ClearID Breast Cancer blood test, which leverages a custom-developed NGS panel of 27 genes known to be altered in breast cancer. The updated test identifies circulating tumor cell burden and detects emerging genetic alterations that are associated with therapy resistance. The assay has been optimized to monitor patients with advanced breast cancer during the start of therapy and at regular intervals following treatment. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.